If you have never been treated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), your doctor may prescribe VENCLEXTA in combination with GAZYVA® (obinutuzumab), an antibody infusion (IV) therapy. 

VENCLEXTA + GAZYVA offers a chance for a treatment-free period after 12 months

In a clinical study of 432 people with previously untreated CLL, VENCLEXTA + GAZYVA was compared to a common chemotherapy + antibody treatment.

The study found that with VENCLEXTA + GAZYVA (216 people):

  • The chance of disease worsening or death was 67% lower compared to the chemotherapy + antibody treatment (216 people)
  • 1 year after the 12-month treatment was completed, nearly 9 out of 10 people were alive and did not experience a worsening of their disease.